Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 2, 2015, Pages 271-280

  Eckmann, Christian ^a   Solomkin, Joseph ^b  

^a Visceral and Thoracic Surgery   (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Ceftolozane tazobactam; Complicated intra abdominal infection; Enterobacteriaceae; Gram negative bacteria; Multidrug resistance

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTOLOZANE PLUS TAZOBACTAM; METRONIDAZOLE; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; DRUG COMBINATION; PENICILLANIC ACID; TAZOBACTAM;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; PENICILLANIC ACID;

EID: 84921032081     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.994504     Document Type: Article

References (47)

1. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg 2010;5:9
2. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg 2014;9:37
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50(2):133-64
4. Sartelli M, Catena F, Coccolini F, et al. Antimicrobial management of intra-abdominal infections: literature's guidelines. World J Gastroenterol 2012;18(9):865-71
5. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in a worldwide context: an observational prospective study (CIAOW Study). World J Emerg Surg 2013;8(1):1
6. World Health Organization. Antimicrobial resistance: global report on surveillance. WHO website. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf [Last accessed 20 November 2014]
7. Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011;55(8):3917-21
8. Hawser SP, Badal RE, Bouchillon SK, et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: smart 2002-2010. Int J Antimicrob Agents 2013;41(3):224-8
9. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg 2012;7(1):36
10. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European antimicrobial resistence surveillance network (EARS-Net). ECDC website. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistancesurveillance-europe-2012.pdf> [Last accessed 5 October 2014]
11. Hawser S, Hoban D, Bouchillon S, et al. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011;30(2):173-9
12. Gupta N, Limbago BM, Patel JB, et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53(1):60-7
13. Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). J Antimicrob Chemother 2014;69(10):2713-22
14. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50(1):43-8
15. Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett 2008;18(17):4849-52
16. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014;74(1):31-51
17. Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54(9):3933-7
18. Cross J, Clugston S, Hwang Y, et al. Mechanistic characterization of ceftolozane/tazobactam (TOL/TAZ): high-resolution x-ray crystallographic and binding/kinetics studies of TOL with P. aeruginosa PBP3 [Poster C-775]. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 5-9 September 2014; Washington, DC
19. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65(9):1972-4
20. Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013;57(12):6305-10
21. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014;58(6):3091-9
22. Maseda E, Aguilar L, Gimenez MJ, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther 2014;12(11):1311-24
23. Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70(1):137-41
24. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozanetazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013;57(11):5707-9
25. Lepak AJ, Reda A, Marchillo K, et al. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2014;58(10):6311-14
26. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2014;58(2):1218-23
27. VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 2013;57(9):4134-8
28. VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane/tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother 2014;58(10):6024-31
29. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51(3):826-30
30. Melham M, Forrest A, Rubino CM, et al. Pharmacokinetic-pharmacodynamic (PKPD) target attainment (TA) analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Pseudomonas aeruginosa [Poster P1743]. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
31. Sader HS, Farrell DJ, Flamm RK, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014;69(3):266-77
32. Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55(5):2390-4
33. McCurdy S, Peterson PJ, Steenbergen JN, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing intra-abdmonial infections in European hospitals (2011-2012): a report from an international antimicrobial surveillance programme [Poster eP446]. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
34. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57(4):1577-82
35. Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;56(6):3086-91
36. Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane/tazobactam. Antimicrob Agents Chemother 2014;58(4):2249-55
37. Wooley M, Bernardo P, Miller B, et al. Evaluation of the potential for drug-drug interactions between ceftolozane/tazobactam and drugs metabolized by CYP1A2 or CYP3A4 or transported by OAT1 or OAT2 [Poster eP450]. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
38. Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, Phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014;58(9):5350-7
39. Wagenlehner F, Umeh O, Huntington J, et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)/pyelonephritis in hospitalised adults: results from the phase 3 ASPECT-cUTI trial [Poster eP449]. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
40. Eckmann C, Hershberger E, Miller B, et al. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalized adults: results from the phase 3 ASPECT-cIAI trial [Poster P0266a]. Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
41. Takesue Y, Nakajima K, Ichiki K, et al. Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. J Hosp Infect 2010;75(1):28-32
42. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15(10):1351-70
43. PRIMAXIN [summary of product characteristics]. Merck & Co, Inc; Whitehouse Station, NJ: 2012
44. MERREM [summary of product characteristics]. AstraZeneca Pharmaceuticals LP; Wilmington, DE: 2013
45. INVANZ [summary of product characteristics]. Merck & Co, Inc; Whitehouse Station NJ: 2014
46. ZOSYN [summary of product characteristics]. Pfizer, Inc; Philadelphia PA: 2012
47. TYGACIL [prescribing information]. Pfizer, Inc; Philadelphia PA: 2013